通过腹膜系膜切除术和靶向区室淋巴结切除术 (PMMR TCL) 进行癌野手术治疗子宫内膜癌 (EC)，旨在实现最佳的局部肿瘤控制，而无需辅助放疗。在之前的出版物中，我们可以证明该方法的可行性，并提供了令人鼓舞的第一个肿瘤学数据。在 2021 年出版物之后，我们在更大的队列中提供了 PMMR TCL 治疗 EC 的数据，并进行了更长的随访。100 2016 年至 2023 年，国际妇产科联盟 (FIGO) I-IV 的 35 名 EC 患者 (75.6%FIGO I) 通过 PMMR TCL 接受了 EC 的癌症现场手术。我们队列的平均随访时间为 27.5 个月 (0, 83; 19.7)。该手术可行且安全，术中和术后并发症发生率良好。尽管 50.4% 的患者有遵循国家和国际指南进行术后放疗的指征，但术后放疗率仅为 10.4%。总体复发率为 8.1%，我们观察到 2 例（1.5%）孤立的局部复发。我们的结果证实了 PMMR TCL 在 EC 患者中的可行性和安全性。肿瘤学数据非常令人鼓舞，并暗示无需辅助照射即可实现优越的局部区域控制。需要更大规模的研究和更长时间的随访来证实这些结果。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

Cancer-field surgery by peritoneal mesometrial resection and targeted compartmental lymphadenectomy (PMMR+TCL) for the treatment of endometrial cancer (EC) aims at optimal locoregional tumor control without the need for adjuvant radiotherapy. In a previous publication we could demonstrate the feasibility of the method and presented encouraging first oncologic data.Following up our 2021 publication, we present data on the treatment of EC by PMMR+TCL in much larger cohort and with longer follow-up.One hundred and thirty-five patients with EC International Federation of Gynecology and Obstetrics (FIGO) I-IV (75.6% FIGO I) underwent cancer field surgery via PMMR+TCL for EC in the years 2016-2023. Mean follow-up in our cohort was 27.5 months (0, 83; 19.7). The procedure was feasible and safe with favorable intra-and postoperative complication rates. Even though 50.4% of patients had an indication for postoperative radiotherapy following national and international guidelines, the rate of postoperative irradiation administered was 10.4%. The overall recurrence rate was 8.1% and we observed 2 (1.5%) isolated locoregional recurrences.Our results confirm the feasibility and safety of PMMR+TCL in EC patients. Oncologic data are very encouraging and hint at a superior locoregional control without adjuvant irradiation. Larger studies with longer follow-up will be needed to confirm these results.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.